KR910018039A - 양특이성 단일클론 항체, 이들의 생산 및 이용 - Google Patents

양특이성 단일클론 항체, 이들의 생산 및 이용 Download PDF

Info

Publication number
KR910018039A
KR910018039A KR1019910005314A KR910005314A KR910018039A KR 910018039 A KR910018039 A KR 910018039A KR 1019910005314 A KR1019910005314 A KR 1019910005314A KR 910005314 A KR910005314 A KR 910005314A KR 910018039 A KR910018039 A KR 910018039A
Authority
KR
South Korea
Prior art keywords
protease
thrombolytic
bispecific antibody
substance
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019910005314A
Other languages
English (en)
Korean (ko)
Inventor
히로 야마자끼
겐지로 다노우에
스스무 이와사
도모후미 구로까와
Original Assignee
우메모또 요시마사
다께다야꾸힝 고오교가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우메모또 요시마사, 다께다야꾸힝 고오교가부시끼가이샤 filed Critical 우메모또 요시마사
Publication of KR910018039A publication Critical patent/KR910018039A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1019910005314A 1990-04-02 1991-04-02 양특이성 단일클론 항체, 이들의 생산 및 이용 Ceased KR910018039A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP8898590 1990-04-02
JP88985/1990 1990-04-02
JP17712190 1990-07-03
JP177121/1990 1990-07-03

Publications (1)

Publication Number Publication Date
KR910018039A true KR910018039A (ko) 1991-11-30

Family

ID=26430304

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910005314A Ceased KR910018039A (ko) 1990-04-02 1991-04-02 양특이성 단일클론 항체, 이들의 생산 및 이용

Country Status (9)

Country Link
US (1) US5496549A (enExample)
EP (1) EP0450479B1 (enExample)
KR (1) KR910018039A (enExample)
AT (1) ATE141285T1 (enExample)
CA (1) CA2039259A1 (enExample)
DE (1) DE69121272T2 (enExample)
HU (1) HUT63203A (enExample)
IE (1) IE76288B1 (enExample)
TW (1) TW212184B (enExample)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001355A (en) * 1982-12-14 1999-12-14 Dowdle; Eugene Bernard Davey Pro-tPA for the treatment of thrombosis, embolism and related conditions
US6017512A (en) * 1992-06-23 2000-01-25 Diatide, Inc. Radiolabeled peptides
US5620675A (en) * 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
HU220347B (hu) * 1994-07-11 2001-12-28 Board Of Regents The University Of Texas System Készítmény az érrendszer specifikus koagulálásához
US5869274A (en) * 1995-08-09 1999-02-09 Zymed Laboratories, Inc. Immuno-histochemical method that reduces background staining
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2349333A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
JP2002532440A (ja) 1998-12-18 2002-10-02 デュポン ファーマシューティカルズ カンパニー ビトロネクチン受容体拮抗剤薬剤
US7660415B2 (en) * 2000-08-03 2010-02-09 Selinfreund Richard H Method and apparatus for controlling access to storage media
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
PT2308888T (pt) 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
WO2005035753A1 (ja) * 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
US20080075712A1 (en) * 2003-10-14 2008-03-27 Kunihiro Hattori Double Specific Antibodies Substituting For Functional Proteins
EP2135619A1 (en) 2003-12-10 2009-12-23 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
DK1876236T3 (da) * 2005-04-08 2014-10-20 Chugai Pharmaceutical Co Ltd Antistof som funktionel erstatning for blodkoagulationsfaktor VIII
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
US8354106B2 (en) 2005-06-16 2013-01-15 The Feinstein Institute For Medical Research Antibodies against HMGB1 and fragments thereof
ES2410406T3 (es) 2005-06-30 2013-07-01 Janssen Biotech, Inc. Anticuerpos anti-IL-23, composiciones, procedimientos y usos
EP3219328B1 (en) 2005-12-29 2020-06-17 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, method and uses
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN105177091A (zh) 2006-03-31 2015-12-23 中外制药株式会社 用于纯化双特异性抗体的抗体修饰方法
CN106519025B (zh) 2007-09-26 2021-04-23 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
PH12012501884B1 (en) 2010-03-30 2018-04-13 Janssen Biotech Inc Humanized il-25 antibodies
US9315585B2 (en) 2010-06-19 2016-04-19 Memorial Sloan Kettering Cancer Center Anti-GD2 antibodies
RU2620071C2 (ru) 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
CA2903576C (en) 2013-03-15 2021-06-08 Nai-Kong V. Cheung High affinity anti-gd2 antibodies
JP2016527225A (ja) 2013-07-15 2016-09-08 ノヴォ ノルディスク アー／エス ウロキナーゼ型プラスミノーゲン活性化因子に結合する抗体
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
MY182431A (en) 2013-12-24 2021-01-25 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2016187068A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
BR112017027870A2 (pt) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista
EP3395835B1 (en) 2015-12-25 2021-02-03 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
CA3004288C (en) 2015-12-28 2025-05-27 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE CLEARANCE EFFICIENCY OF A POLYPEPTIDE CONTAINING THE FC REGION
MX2018009800A (es) 2016-02-12 2018-11-09 Janssen Pharmaceutica Nv Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
US10765724B2 (en) 2016-03-29 2020-09-08 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-IL12/23 antibody
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
TWI820000B (zh) 2016-04-28 2023-11-01 日商中外製藥股份有限公司 含抗體製劑
EP3507305A1 (en) 2016-09-02 2019-07-10 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
JP7125932B2 (ja) 2016-09-06 2022-08-25 中外製薬株式会社 凝固第ｉｘ因子および／または活性化凝固第ｉｘ因子ならびに凝固第ｘ因子および／または活性化凝固第ｘ因子を認識する二重特異性抗体の使用法
MA46366A (fr) 2016-09-30 2019-08-07 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23
CA3044244A1 (en) 2016-11-16 2018-05-24 Janssen Biotech, Inc. Method of treating psoriasis with anti-il23 specific antibody
US20180230218A1 (en) 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
KR20240038148A (ko) 2017-02-07 2024-03-22 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
EP3690050A4 (en) 2017-09-29 2021-06-16 Chugai Seiyaku Kabushiki Kaisha MULTISPECIFIC ANTIGENBINDING MOLECULE WITH BLOOD CLOG FACTOR VIII (FVIII) COFACTOR FUNCTION SUBSTITUATING ACTIVITY AND PHARMACEUTICAL FORMULATION WITH THIS MOLECULE AS THE ACTIVE SUBSTANCE
AR113816A1 (es) 2017-11-01 2020-06-17 Chugai Pharmaceutical Co Ltd Variantes e isoformas de anticuerpos con actividad biológica reducida
MA50580A (fr) 2017-11-06 2020-09-16 Janssen Biotech Inc Méthode sûre et efficace de traitement de l'arthrite psoriasique par un anticorps spécifique anti-il23
US20190269757A1 (en) 2018-03-05 2019-09-05 Janssen Biotech, Inc. Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
WO2019215701A1 (en) 2018-05-11 2019-11-14 Janssen Biotech, Inc. Methods of treating depression using il-23 antibodies
US11241417B2 (en) 2018-06-21 2022-02-08 Yumanity Therapeutics, Inc. Compositions and methods for the treatment and prevention of neurological disorders
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
JP7634474B2 (ja) 2018-07-18 2025-02-21 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
MY206180A (en) 2019-04-17 2024-12-03 Novo Nordisk As Bispecific antibodies
KR20220012883A (ko) 2019-05-23 2022-02-04 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용요법으로 염증성 장질환을 치료하는 방법
BR112021024401A2 (pt) 2019-06-03 2022-04-19 Janssen Biotech Inc Anticorpos anti-tnf, composições e métodos para o tratamento de espondilite anquilosante ativa
CN114025796A (zh) 2019-06-04 2022-02-08 詹森生物科技公司 用抗il23特异性抗体治疗银屑病关节炎的安全且有效的方法
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
KR20230006551A (ko) 2020-05-05 2023-01-10 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
BR112022023489A2 (pt) 2020-05-21 2023-03-14 Janssen Biotech Inc Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
EP4178616A4 (en) 2020-07-13 2024-07-24 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD FOR TREATING PSORIATIC ARTHRITIS USING A SPECIFIC ANTI-IL23 ANTIBODY
AU2022232007A1 (en) 2021-03-12 2023-10-26 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
WO2022190033A1 (en) 2021-03-12 2022-09-15 Janssen Biotech, Inc. Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
EP4423126A1 (en) 2021-10-29 2024-09-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
AU2022388887A1 (en) 2021-11-15 2024-07-04 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
US20230159633A1 (en) 2021-11-23 2023-05-25 Janssen Biotech, Inc. Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
WO2023187707A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of treating mild to moderate psoriasis with il-23 specific antibody
WO2023215498A2 (en) 2022-05-05 2023-11-09 Modernatx, Inc. Compositions and methods for cd28 antagonism
CN119768427A (zh) 2022-05-18 2025-04-04 詹森生物科技公司 用于评估il23抗体以及用il23抗体治疗银屑病关节炎的方法
WO2024097639A1 (en) 2022-10-31 2024-05-10 Modernatx, Inc. Hsa-binding antibodies and binding proteins and uses thereof
EP4623001A1 (en) 2022-11-22 2025-10-01 Janssen Biotech, Inc. Method of treating ulcerative colitis with anti-il23 specific antibody
WO2024118866A1 (en) 2022-12-01 2024-06-06 Modernatx, Inc. Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
WO2024206126A1 (en) 2023-03-27 2024-10-03 Modernatx, Inc. Cd16-binding antibodies and uses thereof
WO2025196691A1 (en) 2024-03-20 2025-09-25 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
JP3177776B2 (ja) * 1988-09-27 2001-06-18 武田薬品工業株式会社 ハイブリッドモノクローナル抗体，抗体産生ポリドーマおよび抗体含有薬剤
CA1213229A (en) * 1982-04-12 1986-10-28 Gary S. David Antibodies having dual specificities, their preparation and uses therefor
WO1985004811A1 (en) * 1984-04-23 1985-11-07 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
DE3426903A1 (de) * 1984-07-20 1986-01-23 Biotest Pharma GmbH, 6000 Frankfurt Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten
EP0241907A3 (en) * 1986-04-14 1989-09-13 The General Hospital Corporation Heterobifunctional antibodies and method of use
US4889922A (en) * 1986-08-13 1989-12-26 Monsanto Co. Monoclonal antibody specific for human colon fibroblast-derived T-PA
DE3909708A1 (de) * 1989-03-23 1990-09-27 Boehringer Mannheim Gmbh Verfahren zur herstellung bispezifischer antikoerper

Also Published As

Publication number Publication date
TW212184B (enExample) 1993-09-01
CA2039259A1 (en) 1991-10-03
IE911079A1 (en) 1991-10-09
HU911027D0 (en) 1991-10-28
EP0450479B1 (en) 1996-08-14
IE76288B1 (en) 1997-10-08
DE69121272D1 (de) 1996-09-19
HUT63203A (en) 1993-07-28
DE69121272T2 (de) 1997-01-09
US5496549A (en) 1996-03-05
EP0450479A1 (en) 1991-10-09
ATE141285T1 (de) 1996-08-15

Similar Documents

Publication Publication Date Title
KR910018039A (ko) 양특이성 단일클론 항체, 이들의 생산 및 이용
Kurlander et al. The binding of human immunoglobulin G1 monomer and small, covalently cross-linked polymers of immunoglobulin G1 to human peripheral blood monocytes and polymorphonuclear leukocytes
Jemmerson et al. Phosphatidylinositol anchor of HeLa cell alkaline phosphatase
GB1533205A (en) Plasmin fractions and complexes thereof
Gaussem et al. Sodium dodecyl sulfate-induced dissociation of complexes between human tissue plasminogen activator and its specific inhibitor
Huang et al. Thiol-disulfide isomerization in thrombospondin: effects of conformation and protein disulfide isomerase
Yoshida et al. Modulation of the receptor for urokinase-type plasminogen activator in macrophage-like U937 cells by inflammatory mediators
JPS58129998A (ja) 標識蛋白質性阻害剤を用いるプロテア−ゼの分析法
GB9507985D0 (en) Antibody to aminoterminal propeptide to type 1 procollagen and assay method using it
FR2563630B1 (fr) Anticorps monoclonaux anticytomegalovirus et procedes pour le diagnostic in vitro des infections par les cytomegalovirus humains et d'une proteine-kinase inductible par les cytomegalovirus et susceptible d'etre reconnue par les susdits anticorps monoclonaux
DE69020548D1 (de) Blutplättchenspezifische immunokonjugate.
KR890002663A (ko) 조직 플라스미노겐 활성화제의 활성을 측정하는 방법, 장치 및 키트
ES8603951A1 (es) Un metodo de estabilizar el zimogeno de uroquinasa
DE3850993D1 (de) Monoklonaler Antikörper spezifisch gegen humane Pankreas-Phospholipase-A2.
KR900015759A (ko) 조직 플라스미노겐 활성인자(t-PA)의 작용 반감기를 연장시키는, t-PA에 대한 모노클로날 항체
KR900004351A (ko) 하이브리드 단일클론 항체, 그의 제조방법 및 용도
Kurosawa-Ohsawa et al. Anti-protein C monoclonal antibody induces thrombus in mice
FI861715A0 (fi) Monoklonal antiurokinase-antikropp, den innehaollande matris och biokemiska testpackningar, i vilka den anvaendes.
FR2718849B1 (fr) Procédé d'immunodosage de l'antithrombine III activée par un glycosaminoglycane, anticorps monoclonaux correspondants et leur procédé d'obtention.
ATE97324T1 (de) Verwendung von amphipatischen molekuelen zur radiodarstellung und therapie mittels monoklonaler oder polyklonaler antikoerperkonjugate.
Chen et al. A simple efficient production of neoantigenic antisera against fibrinolytic degradation products: radioimmunoassay of fragment E
NL8601240A (nl) Plasminogeenactivator en trombolytisch geneesmiddel.
Reddy et al. Differential autolysis of human and canine plasmins
GORMSEN et al. Degradation of Fibrinogen in vitro: Demonstration of Several Antigenic Intermediates by Specific Anti‐D and Anti‐E Serum
Ozato et al. Enzymatic activities of the soluble antigens in kidney microsomes

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000